As aging progresses, the quality of DNA and proteins inside cells declines, which is known to be the cause of various ...

Over the last few years, scientists and entrepreneurs have flocked to developing medicines that target RNA, the genetic ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

Yale researchers have developed a new and safe family of RNA-editing tools that utilize an RNA-targeting activity that they ...

The quest for a vaccine against HIV has been going on for about 40 years — almost as long as the virus that causes AIDS has ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera ...

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.

In 1957, just four years after Francis Crick and other scientists solved the riddle of DNA’s structure—the now famous double ...

The US Food and Drug Administration (FDA) has approved Dawnzera (donidalorsen) for prophylaxis to prevent attacks of ...

The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...